To explore the efficacy and safety of Bawei Yijing capsules combined with western medicine in the treatment of systemic sclerosis (SSc) of Yang deficiency and cold coagulation type, as well as its influence on the levels of T lymphocyte subsets.
A total of 112 patients with SSc admitted to our hospital from November 2020 to October 2022 were selected and randomly divided into the conventional group and the combined group, with 56 cases in each group. The conventional group received basic western medical treatment, while the combined group was treated with Bawei Yijing capsules on the basis of the conventional group. Both groups were treated for 12 weeks continuously.The changes of skin hardness scores and the levels of T lymphocyte subsets before and after treatment were recorded in both groups, respectively. Meanwhile, the clinical efficacy and the occurrence of adverse reactions in the two groups were observed and compared.
After treatment, the total effective rate of the conventional group was lower than that of the combined group (75.00% vs. 94.64%, P<0.05). The skin hardness scores of both groups decreased compared with those before treatment (P<0.05), and the combined group showed a greater decrease (P<0.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ in both groups increased compared with before, while the positive rates of anti-SCL-70 antibody, anti-SSA/Ro-52kD antibody, pulmonary artery inner diameter, Furst's visceral score, and CD8+ level decreased compared with before (P<0.05). Moreover, the combined group showed greater increases in CD3+, CD4+, and CD4+/CD8+ levels (P<0.05), and greater decreases in the positive rates of anti-SCL-70 antibody, anti-SSA/Ro-52kD antibody, pulmonary artery inner diameter, Furst's visceral score, and CD8+ level (P<0.05). There was no significant difference in the incidence of adverse reactions between the groups during the treatment period (12.50% vs. 10.71%, P>0.05).
Bawei Yijing capsules combined with western medicine in the treatment of SSc can significantly improve the clinical efficacy, effectively alleviate the condition of patients, regulate the levels of T lymphocyte subsets, and has better safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |